Therapeutic vaccine TG4001 combined with Avelumab for advanced HPV-positive cancer: clinical trials yielded positive results.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- The human papillomavirus (HPV) is a virus that causes abnormal tissue growth and other changes in cells.it can be infected by skin contact during sex, and HPV can be carried in any sex.about 12 to 14 high-risk strains of HPV, strains 16 and 18 are the cause of most HPV cancer.fact, these two strains not only cause 70% of cervical cancer, but also cause most oral, vaginal, vulvar and penile cancers. Data analysis of the Ib/II trial bybiotechnology company Transgene showed significant effectiveness in the treatment of recurrent and/or metastatic HPV16-positive malignancies in the HPV16 therapeutic vaccine TG4001 combined anti-PD-L1 antibody Avelumab (BAVENCIO ®).the trial was conducted in collaboration with Merck and Pfizer.the purpose of this exploratory Ib / II trial is to assess the safety and efficacy of TG4001 and immunocheckpoint inhibitors in combination treatment of invasive, recurrent and/or metastatic HPV16-positive cancers. a total of 34 cases of assessable oral,, cervical or other HPV16-positive cancer patients were enrolled in the.trial results are consistent with the data published in ESMO 2019 and durable mitigation was observed in most patients.at present, the patient's follow-up is still ongoing.full data will be presented at the upcoming scientific conference..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
